Aaron is a multi-faceted scientist with research experience ranging from cell engineering to single molecule analyses, as well as cell biology work in cancer, fibrosis and mitochondrial diseases. Prior to joining Volastra, Aaron worked at Inzen Therapeutics, a company developing therapies based on insights into cell death in disease. Aaron received his B.S. in chemistry from Union College and an M.S. in chemistry from Tufts University. Aaron completed his Ph.D. in cell and molecular biology at the Vilcek Institute of Graduate Biomedical Sciences at NYU in Agnel Sfeir’s lab, where he studied mitochondrial DNA replication and repair at the single molecule level.